Zimmer Biomet (ZBH) Stock Price, Fundamentals & Analysis

What ZBH does

Zimmer Biomet (ZBH) is a Healthcare sector stock in the Medical Devices industry, headquartered in Warsaw, United States. The company designs, manufactures, and markets orthopedic reconstructive products such as knees and hips, sports medicine and biologics, craniomaxillofacial and thoracic products, and integrated digital and robotic technologies used to treat bone, joint, and soft-tissue conditions worldwide.

Key numbers explained

• ZBH trades at 90.88 USD, down 3.3% today, with a market capitalisation of 17.33B USD, placing it among large-cap Medical Devices names.
• The trailing P/E ratio of 22.1 shows how much investors pay per dollar of the last twelve months' earnings; the forward P/E ratio of 10 reflects a lower price relative to expected future earnings.
• Earnings per share over the trailing twelve months is 4.12 USD, while the dividend yield of 1.02% indicates the annual dividend as a percentage of the current share price.
• The ex-dividend date is 30 Sept. 2026, and the company pays out 23% of its earnings as dividends.
• With a beta of 0.47, ZBH has historically moved less than the overall market, and its 52-week range of 79.12 – 106.88 USD shows the recent price spread.
• Revenue for the trailing twelve months is 8.51B USD, growing 4.8% year over year, with a profit margin of 9.5% and an operating margin of 18%.
• The debt-to-equity ratio of 60.2% and price-to-book of 1.37 describe the company's leverage and how its market value compares with its book value.
• ZBH is part of the S&P 500, and investors often compare it with peers such as Edwards Lifesciences (EW), Idexx Laboratories (IDXX), Humana (HUM), Mettler Toledo (MTD), Quest Diagnostics (DGX), and DaVita (DVA).

Recent news

Recent headlines note that Zimmer Biomet traded down alongside Surgery Partners, 10x Genomics, QuidelOrtho, and Tandem Diabetes, and appear in a global report benchmarking the Minimally Invasive Robotic Surgical System market against Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker, and Zimmer Biomet. Other stories highlight mid-cap stocks with open questions and the growing role of ambulatory surgery centers in the competitive landscape.

What to watch

Investors tracking ZBH often watch the Medical Devices sector's regulatory environment, product-cycle updates, and reimbursement trends, as well as broader market factors that affect large-cap healthcare names like those in the S&P 500. Comparing ZBH's margins, growth, and valuation with peers such as Edwards Lifesciences (EW), Idexx Laboratories (IDXX), Humana (HUM), Mettler Toledo (MTD), Quest Diagnostics (DGX), and DaVita (DVA) can help frame its position within Healthcare.